Chronic hepatitis represents the natural course of hepatitis C virus (HCV) infection in a high percentage of patients. Many publications have shown different events involved in HCV pathogenesis, proposing an important role, both for the immune response and for the genetic ability of the virus to escape host defences (1). During its natural history among infected patients, a reasonable percentage (13-33%) develops type 2 diabetes mellitus (DM) (2-3). In recent years, tumor necrosis factor-alpha (TNF-a), a proinflammatory cytokine induced by HCV during the infection (4), has been identified as a possible mediator of insulin resistance in murine models (5) and probably involved in DM during chronic hepatitis C (CHC) too, (2-3). In the light of current literature publication and our previous experience on TNF-a in metabolic liver disease ( 6), we assayed this cytokine in patients suffering from CHC, both with and without diabetes to search for a possible relationships. We enrolled 30 naive patients from our department (15 Group A with CHC + DM and 15 Group B with only CHC) on the basis ofthe following selection criteria: CHC histologically proven, negativity for autoimmune markers (ANA, anti-LKM, AMA), absence of alcohol abuse, no co-infection' (HBV, HIV), increased ALT and AST levels (upper two times limit with normal value < 40UI/L), positive HCV-RNA qualitative assay, no hypertrigliceridemia or hypercholesterolemia and presence of diabetes mellitus (for group A the only; in accordance with international diagnostic criteria). In these select groups we examined, by ELISA the TNF-a, as well as ALT, AST, genotype (all patients were genotype 1b) and plasma level for the glucose. The results were evaluated by non-parametric tests, for possible correlation or difference among these parameters, using the Spearman and U MannWhitney tests (Table I ).
An increased level of TNF-a was detected both in the group A and in patients with only viral infection, but without any statistical difference (U Mann-Whitney test z =-.1601 p = .8575) (Fig.  1) . We also did not find any correlation among TNF-a, AST, ALTor glucose plasma levels. Such preliminary data, even if derived from a narrow cohort, display any important considerations about the role ofTNF-a in DM during CHC. Indeed, our study did not show any difference in serum TNFa levels between the two groups, suggesting the lack of TNF-a usefulness in characterizing DM during chronic HCV disease, at least for genotype 1b. Any increased level could simply reflect an inflammatory state during chronic infection, as already reported (5) without a pivotal role on carbohydrate metabolism. Our data appear to be in disagreement with other studies concerning the role ofTNF-a in the course ofDM during HeV (3) (4) . This discordance may reflect different cytokine environment in different stages of glucose metabolism during natural history of the CHC, as o Median va lue occurs in non alcoholic steatohepatitis (6) . Alternatively, there may be some viral effect on different liver functions (7); it would be therefore important to investigate any possible direct metabolic alterations in response to viral activity that in time could contribute to DM.
In conclusion, we think that a multi factorial pathogenesis should be considered for the carbohydrate metabolism alterations noted during CHC. We suggest that other mechanisms and other cytokines should be considered to promote a better evaluation of the pathogenesis and clearer categorization of DM during CHC. 
